European Medicines Agency has validated the application for Bavencio in combination with Inlyta for the treatment of patients with advanced renal cell carcinoma.
Merck and Pfizer Inc. announced that the European Medicines Agency (EMA) has validated for review the Type II variation application for Bavencio (avelumab) in combination with Inlyta (axitinib) for the treatment of patients with advanced renal cell carcinoma (RCC). With this validation, the application is complete, and the EMA will now begin the review procedure.
The application is based on results from the pivotal Phase III JAVELIN Renal 101 trial, which were published in the New England Journal of Medicine on February 16, 2019. The FDA has also accepted a supplemental Biologics License Application for Bavencio in combination with Inlyta for patients with advanced RCC for Priority Review, with a target action date in June 2019. A supplemental application for the combination in unresectable or metastatic RCC has also been submitted in Japan.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.